FB Nasdaq FB Facebook
Finance

Healthcare Movers: Intercept Pharmaceuticals Inc. (NASDAQ:ICPT), Pernix Therapeutics (NASDAQ:PTX), Galena Biopharma (NASDAQ:GALE), Teva Pharmaceutical Industries Ltd. (NYSE:TEVA)

Intercept Pharmaceuticals Inc. (NASDAQ:ICPT) is lower after the company reported mixed Q4 and full-year 2013 earnings, as well as releasing results for its Phase 3 POISE trial. Shares are now down 10.71% at $412.75, but are still at the higher end of its 52-week range of $30.38 – $497.00 On Friday, Intercept (NASDAQ:ICPT) reported a loss per share of $0.64, compared to a loss of $2.02 for the same quarter the previous year and better than analyst expectations of a loss of $0.70 per share, if comparable. Revenue for the quarter was flat at $405 million.

Separately, the company disclosed Sunday positive results for its Phase 3 POISE trial of obeticholic acid (OCA) for the treatment of primary biliary cirrhosis (PBC), noting it met the primary endpoint with high statistical significance. Intercept Pharmaceuticals Inc. (NASDAQ:ICPT) also reported that generally mild to moderate pruritus, or itching, was observed as the most frequently reported adverse event associated with OCA treatment.

Pernix Therapeutics (NASDAQ:PTX) is firmer after the company reported mixed financial results for Q4, missing on EPS, but beating on revenue. Shares are up 4.87% at $3.66, with a 52-week range of $1.68 – $6.35. The specialty pharmaceutical company reported a Q4 net loss of $5.6 million, or $0.15 per diluted share, compared with the prior-year period’s net loss of $1.4 million, or $0.05 per diluted share.

Pernix Therapeutics (NASDAQ:PTX)’s revenue was $23.9 million, up 31% from $18.2 million in the same quarter last year. Analysts polled by Capital IQ were expecting a loss per share of $0.08 on revenues of $21.70 million.

Galena Biopharma (NASDAQ:GALE) shares were up 6.7% pre-market Monday as the biotech company prepared to report its Q4 results after the closing bell.

Galena Biopharma (GALE) was trading near $3.37 in a 52-week range of $1.65 to $7.77. Analysts expect a loss of $0.09 and revenue of $1.62 million, according to Capital IQ.

Analysts at RBC Capital Markets have raised their price target on ADRs of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) to $46 from $39 a share. The firm left its sector perform rating on the stock unchanged.

In pre-market trading, shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) are up 0.76% to $49.25, amid a 52-week spread of $36.26 – $51.41.